Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Fielding

Showing results (141-150 of 166) with videos related to

Pageof 17
Sort By:
Haematologica|November 18, 2021
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trialsThomas Creasey, Emilio Barretta, Sarra L Ryan, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Blood Advances|September 3, 2021
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trialRachel J Mitchell, Amy A Kirkwood, Emilio Barretta, et al.
Blood|December 1, 2007
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Anthony H Goldstone, Susan M Richards, Hillard M Lazarus, et al.
Blood|October 16, 2009
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)David I Marks, Elisabeth M Paietta, Anthony V Moorman, et al.
Blood|February 27, 2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Adele K Fielding, Jacob M Rowe, Susan M Richards, et al.
Leukemia|October 17, 2021
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 studyAnthony V Moorman, Emilio Barretta, Ellie R Butler, et al.
Blood Cancer Journal|September 24, 2016
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaN Gökbuget, M Kelsh, V Chia, et al.
British Journal of Haematology|August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemiaRob S Sellar, Varun Mehra, Thomas A Fox, et al.
Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.
Pageof 17

Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
Haematologica|November 18, 2021
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trialsThomas Creasey, Emilio Barretta, Sarra L Ryan, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Blood Advances|September 3, 2021
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trialRachel J Mitchell, Amy A Kirkwood, Emilio Barretta, et al.
Blood|December 1, 2007
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Anthony H Goldstone, Susan M Richards, Hillard M Lazarus, et al.
Blood|October 16, 2009
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)David I Marks, Elisabeth M Paietta, Anthony V Moorman, et al.
Blood|February 27, 2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Adele K Fielding, Jacob M Rowe, Susan M Richards, et al.
Leukemia|October 17, 2021
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 studyAnthony V Moorman, Emilio Barretta, Ellie R Butler, et al.
Blood Cancer Journal|September 24, 2016
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaN Gökbuget, M Kelsh, V Chia, et al.
British Journal of Haematology|August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemiaRob S Sellar, Varun Mehra, Thomas A Fox, et al.
Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.
Pageof 17